The Use of Pan-Tropomyosin Receptor Kinase Immunohistochemistry as a Screening Tool for the Detection of Neurotrophic Tropomyosin-Related Kinase Fusions: Real-World Data from a National Multicentric Retrospective Study
暂无分享,去创建一个
P. Delvenne | B. Weynand | M. V. Van Bockstal | P. Pauwels | L. Craciun | P. Demetter | I. Theate | Bart De Wiest | S. Vander Borght | D. Creytens | L. Habran | F. Dedeurwaerdere | K. Van Der Steen | G. Beniuga | Koen Dewinne | M. V. van Bockstal
[1] A. Sapino,et al. Pursuit of Gene Fusions in Daily Practice: Evidence from Real-World Data in Wild-Type and Microsatellite Instable Patients , 2021, Cancers.
[2] D. Cappellen,et al. MSI-High RAS-BRAF wild-type colorectal adenocarcinomas with MLH1 loss have high frequency of targetable oncogenic gene fusions whose diagnoses are feasible using methods easy-to-implement in pathology laboratories. , 2021, Human pathology.
[3] H. Popper,et al. Applicability of pan-TRK immunohistochemistry for identification of NTRK fusions in lung carcinoma , 2021, Scientific Reports.
[4] F. Jardin,et al. Pan-TRK Immunohistochemistry Is Highly Correlated With NTRK3 Gene Rearrangements in Salivary Gland Tumors , 2021, The American journal of surgical pathology.
[5] L. Weiss,et al. NTRK Fusions and Trk Proteins: What are They and How to Test for Them. , 2021, Human pathology.
[6] Lei Zhu,et al. Identification of NTRK gene fusions in lung adenocarcinomas in the Chinese population , 2021, The journal of pathology. Clinical research.
[7] J. Hornick,et al. Predictive ‘biomarker piggybacking’: an examination of reflexive pan‐cancer screening with pan‐TRK immunohistochemistry , 2021, Histopathology.
[8] P. Pauwels,et al. NTRK Fusions in Sarcomas: Diagnostic Challenges and Clinical Aspects , 2021, Diagnostics.
[9] Marilyn M. Li,et al. NTRK Fusions Identified in Pediatric Tumors: The Frequency, Fusion Partners, and Clinical Outcome , 2021, JCO precision oncology.
[10] Dijana Cerjan,et al. Evaluation of NTRK immunohistochemistry as a screening method for NTRK gene fusion detection in non-small cell lung cancer. , 2020, Lung cancer.
[11] B. Weynand,et al. Immunohistochemistry as a screening tool for NTRK gene fusions: results of a first Belgian ring trial , 2020, Virchows Archiv.
[12] Harn-Shen Chen,et al. Detection of NTRK1/3 Rearrangements in Papillary Thyroid Carcinoma Using Immunohistochemistry, Fluorescent In Situ Hybridization, and Next-Generation Sequencing , 2020, Endocrine Pathology.
[13] I. Brčić,et al. Broadening the spectrum of NTRK rearranged mesenchymal tumors and usefulness of pan-TRK immunohistochemistry for identification of NTRK fusions , 2020, Modern Pathology.
[14] A. Vargas,et al. NTRK-rearranged mesenchymal tumours: diagnostic challenges, morphological patterns and proposed testing algorithm. , 2020, Pathology.
[15] M. Ladanyi,et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. , 2020, The Lancet. Oncology.
[16] Y. Oda,et al. Diagnostic utility of pan‐Trk immunohistochemistry for inflammatory myofibroblastic tumours , 2020, Histopathology.
[17] C. Antonescu,et al. Pan‐Trk immunohistochemistry is a sensitive and specific ancillary tool for diagnosing secretory carcinoma of the salivary gland and detecting ETV6–NTRK3 fusion , 2020, Histopathology.
[18] R. Weber,et al. Pan-Trk immunohistochemistry reliably identifies ETV6-NTRK3 fusion in secretory carcinoma of the salivary gland , 2020, Virchows Archiv.
[19] B. Taylor,et al. TRK Fusions Are Enriched in Cancers with Uncommon Histologies and the Absence of Canonical Driver Mutations , 2019, Clinical Cancer Research.
[20] A. Drilon,et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. , 2019, The Lancet. Oncology.
[21] A. Chou,et al. NTRK gene rearrangements are highly enriched in MLH1/PMS2 deficient, BRAF wild-type colorectal carcinomas—a study of 4569 cases , 2019, Modern Pathology.
[22] A. Drilon. TRK inhibitors in TRK fusion-positive cancers. , 2019 .
[23] M. Ladanyi,et al. Identifying patients with NTRK fusion cancer. , 2019 .
[24] M. Hummel,et al. Analysis of NTRK expression in gastric and esophageal adenocarcinoma (AGE) with pan-TRK immunohistochemistry. , 2019, Pathology, research and practice.
[25] A. Vincent-Salomon,et al. Pan-TRK Immunohistochemistry , 2019, The American journal of surgical pathology.
[26] M. Ladanyi,et al. ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[27] M. Ladanyi,et al. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls , 2019, Modern Pathology.
[28] Y. Hung,et al. Immunohistochemistry with a pan‐TRK antibody distinguishes secretory carcinoma of the salivary gland from acinic cell carcinoma , 2019, Histopathology.
[29] I. Yeh,et al. Filigree-like Rete Ridges, Lobulated Nests, Rosette-like Structures, and Exaggerated Maturation Characterize Spitz Tumors With NTRK1 Fusion , 2019, The American journal of surgical pathology.
[30] F. Penault-Llorca,et al. Testing algorithm for identification of patients with TRK fusion cancer , 2019, Journal of Clinical Pathology.
[31] Jessica L. Davis,et al. Expanding the Spectrum of Pediatric NTRK-rearranged Mesenchymal Tumors , 2019, The American journal of surgical pathology.
[32] F. Guyon,et al. Uterine and vaginal sarcomas resembling fibrosarcoma: a clinicopathological and molecular analysis of 13 cases showing common NTRK-rearrangements and the description of a COL1A1-PDGFB fusion novel to uterine neoplasms , 2019, Modern Pathology.
[33] P. Marcorelles,et al. Non‐secretory breast carcinomas lack NTRK rearrangements and TRK protein expression , 2019, Pathology international.
[34] J. Hornick,et al. Immunohistochemical correlates of recurrent genetic alterations in sarcomas , 2019, Genes, chromosomes & cancer.
[35] Liliana Villafania,et al. Colorectal Carcinomas Containing Hypermethylated MLH1 Promoter and Wild-Type BRAF/KRAS Are Enriched for Targetable Kinase Fusions. , 2019, Cancer research.
[36] A. Drilon,et al. NTRK fusion-positive cancers and TRK inhibitor therapy , 2018, Nature Reviews Clinical Oncology.
[37] J. Swensen,et al. Molecular characterization of cancers with NTRK gene fusions , 2018, Modern Pathology.
[38] K. White,et al. Genomic Fusions in Pigmented Spindle Cell Nevus of Reed , 2018, The American journal of surgical pathology.
[39] A. Shoushtari,et al. Primary and Metastatic Melanoma With NTRK Fusions , 2018, The American journal of surgical pathology.
[40] C. Fletcher,et al. Evaluation of pan‐TRK immunohistochemistry in infantile fibrosarcoma, lipofibromatosis‐like neural tumour and histological mimics , 2018, Histopathology.
[41] Jessica L. Davis,et al. Pan-Trk Immunohistochemistry Identifies NTRK Rearrangements in Pediatric Mesenchymal Tumors , 2018, The American journal of surgical pathology.
[42] Funda Meric-Bernstam,et al. Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children , 2018, The New England journal of medicine.
[43] James X. Sun,et al. ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer , 2017, Journal of the National Cancer Institute.
[44] M. Ladanyi,et al. Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions , 2017, The American journal of surgical pathology.
[45] I. Yeh,et al. NTRK3 kinase fusions in Spitz tumours , 2016, The Journal of pathology.
[46] Manish B. Patel,et al. Durable Clinical Response to Entrectinib in NTRK1-Rearranged Non-Small Cell Lung Cancer , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[47] T. Ishida,et al. Congenital-infantile fibrosarcoma. A clinicopathologic study of 10 cases and molecular detection of the ETV6-NTRK3 fusion transcripts using paraffin-embedded tissues. , 2001, American journal of clinical pathology.
[48] P. Sorensen,et al. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma , 1998, Nature Genetics.